AGIO - Agios Pharmaceuticals, Inc.
NEXT EARNINGS:
May 7, 2026
EPS Est: $-1.80
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$41.50
DETAILS
HIGH:
$62.00
LOW:
$25.00
MEDIAN:
$39.50
CONSENSUS:
$41.50
UPSIDE:
36.56%
Market Cap:
1.78B
Volume:
1,175,777
Avg Volume:
1,265,645
52 Week Range:
22.24-46
Sector:
Healthcare
Industry:
Biotechnology
Beta:
0.91
Last Dividend:
$N/A
Exchange:
NASDAQ
Country:
US
Employees:
486
IPO Date:
2013-07-24
EPS (TTM):
-7.12
P/E Ratio:
-3.82
Revenue (TTM):
54.03M
Total Assets:
1.30B
Total Debt:
62.02M
Cash & Equiv:
89.13M
Rev Growth (5Y):
-2.8%
EPS Growth (5Y):
N/A
FCF Growth (5Y):
N/A
ROCE:
-38.9%
Debt/Equity:
0.05
Earnings History
| Date | EPS Actual | EPS Est | EPS Surprise | Rev Actual | Rev Est | Rev Surprise |
|---|---|---|---|---|---|---|
| 2026-02-12 | $-1.86 | $-1.97 | +5.6% | $20.0M | $15.8M | +26.2% |
| 2025-10-30 | $-1.78 | $-1.93 | +7.8% | $12.9M | $11.7M | +10.1% |
| 2025-07-31 | $-1.93 | $-1.74 | -10.9% | $12.5M | $10.3M | +21.2% |
| 2025-05-01 | $-1.55 | $-1.80 | +13.9% | $8.7M | $10.0M | -12.6% |
| 2025-02-13 | $-1.74 | $-1.69 | -3.0% | $10.7M | $9.3M | +14.8% |
| 2024-10-31 | $4.20 | $16.69 | -74.8% | $9.0M | $9.3M | -3.3% |
| 2024-08-01 | $-1.69 | $-1.58 | -7.0% | $8.6M | $9.3M | -7.5% |
| 2024-05-02 | $-1.45 | $-1.64 | +11.6% | $8.2M | $9.8M | -16.0% |
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 54.03M | 36.50M | 26.82M | 14.24M | 0 | 0 | 117.91M | 94.39M | 43.01M | 69.89M | 59.12M | 65.36M |
| Net Income | (412.78M) | 673.73M | (352.09M) | (231.80M) | 1.60B | (327.37M) | (411.47M) | (346.03M) | (314.67M) | (198.47M) | (117.73M) | (53.50M) |
| EPS | -7.12 | 11.86 | -6.33 | -4.23 | -6.36 | -4.74 | -6.61 | -6.03 | -6.75 | -5.07 | -3.15 | -1.59 |
| Total Assets | 1.30B | 1.66B | 937.12M | 1.24B | 1.44B | 852.95M | 890.74M | 858.46M | 614.40M | 619.09M | 420.06M | 491.90M |
| Total Debt | 62.02M | 56.99M | 72.00M | 85.66M | 97.09M | 105.20M | 113.66M | 0 | 0 | 0 | 0 | 0 |
| Cash & Equivalents | 89.13M | 76.25M | 88.20M | 139.26M | 203.13M | 127.44M | 80.93M | 805.42M | 567.75M | 573.56M | 375.91M | 14.03M |
| Operating Cash Flow | (372.98M) | (389.84M) | (296.06M) | (309.48M) | (407.32M) | (290.76M) | (370.62M) | (304.42M) | (285.23M) | 38.56M | (76.95M) | (59.35M) |
| Free Cash Flow | (377.29M) | (391.53M) | (297.06M) | (314.36M) | (413.06M) | (304.87M) | (382.79M) | (311.41M) | (289.86M) | 28.65M | (97.11M) | (61.57M) |
| FCF per Share | -6.51 | -6.89 | -5.34 | -5.74 | -6.83 | -4.42 | -6.38 | -5.42 | -6.22 | 0.73 | -2.59 | -1.83 |
| Book Value | 1.19B | 1.54B | 811.02M | 1.10B | 1.29B | 399.50M | 640.53M | 687.54M | 375.50M | 358.59M | 345.12M | 424.37M |
| Cash & ST Investments | 854.42M | 893.71M | 776.93M | 783.12M | 1.02B | 572.93M | 564.88M | 805.42M | 567.75M | 573.56M | 375.91M | 342.06M |
| ROC Equity | -0.35 | 0.44 | -0.43 | -0.21 | 1.24 | -0.82 | -0.64 | -0.50 | -0.84 | -0.55 | -0.34 | -0.13 |